The global invasive ductal carcinoma treatment market size was estimated to be USD 9.37 billion in 2023 and is expected to reach USD 23.02 billion by 2034 with a CAGR of 8.52% during the forecast period 2024-2034. The market will grow due to factors such as the rising incidence of breast cancer, improvements in targeted therapies, a growing emphasis on personalized medicine, higher investments in research and development, and easier access to healthcare in emerging markets.
One of the main factors driving the IDC treatment market is the emergence of personalized medicine, which involves designing medicines based on a patient's genetic composition and kind of cancer. The utilization of tailored therapeutics and more accurate diagnosis made possible by developments in molecular profiling and genetic testing have improved patient outcomes and increased demand for state-of-the-art medical care. For instance, in January 2023, a targeted medication for advanced breast tumors that are difficult to treat was approved by the U.S. FDA because of the research and advocacy work done by specialists from Duke University and the Duke University Health System.
By therapy, the targeted therapy segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the increasing adoption of personalized medicine, superior efficacy in treating specific molecular subtypes, and fewer side effects compared to traditional chemotherapy. Targeted therapies, such as HER2 inhibitors, have shown substantial success in treating IDC patients, driving their market dominance. For instance, the U.S. FDA authorized Enhertu in April 2024 for the treatment of adult patients with solid tumors that are HER2-positive and metastatic after systemic treatment but do not have adequate alternatives. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing clinical evidence supporting its effectiveness, particularly in cases where traditional treatments have failed. Immunotherapy’s ability to harness the body’s immune system to fight cancer, along with promising results in combination therapies, is expected to significantly boost its demand.
By type, the hormone receptor segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the high prevalence of hormone receptor-positive IDC cases and the effectiveness of hormone therapies like tamoxifen and aromatase inhibitors in managing these types of cancers. Hormone receptor-positive breast cancer treatments remain widely used and generate substantial revenue. For instance, Gilead Sciences stated in February 2023 that the U.S. FDA has approved Trodelvy for a third indication. Through its approval, patients with the most common kind of breast cancer now have an extra therapy choice. Those with metastatic breast cancer, particularly those of the HR-positive/HER2-negative form, who had already undergone at least two systemic treatments and were no longer responding to hormone therapy were the first to be approved for trodelvy. Additionally, the HER2+ segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel HER2-targeting drugs and the increasing use of advanced HER2 inhibitors in patients with aggressive forms of IDC. Innovations in HER2-positive breast cancer treatment, such as the introduction of more potent drugs and combination therapies, are expected to drive rapid growth in this segment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the large volume of cancer treatments administered in hospitals, specialized oncology centers, and the availability of advanced therapies primarily through hospital settings. Patients undergoing complex treatments like chemotherapy and immunotherapy often receive medications directly from hospital pharmacies. For instance, the Max Foundation, working with partners and oncologists, established a program in June 2023 to address the pressing unmet need in low-income nations by giving patients with HR+/HER2- advanced breast cancer access to therapy. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing convenience of online purchasing, growing digital healthcare infrastructure, and the rising demand for home-based care. The shift towards telemedicine and e-commerce, especially following the COVID-19 pandemic, has spurred the growth of online pharmacies, making it easier for patients to access cancer medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to a well-established healthcare infrastructure, high prevalence of breast cancer, and access to advanced treatments. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing healthcare investments, rising cancer awareness, and growing access to advanced treatment options. For instance, in January 2023, the U.S. FDA authorized elacestrant (Orserdu) for the treatment of advanced ER-positive, HER2-negative breast cancer in postmenopausal women and adult males. This medication is especially useful for patients whose cancer has progressed following at least one endocrine therapy line and who have an ESR1 mutation.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
One of the main factors driving the IDC treatment market is the emergence of personalized medicine, which involves designing medicines based on a patient's genetic composition and kind of cancer. The utilization of tailored therapeutics and more accurate diagnosis made possible by developments in molecular profiling and genetic testing have improved patient outcomes and increased demand for state-of-the-art medical care. For instance, in January 2023, a targeted medication for advanced breast tumors that are difficult to treat was approved by the U.S. FDA because of the research and advocacy work done by specialists from Duke University and the Duke University Health System.
By therapy, the targeted therapy segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the increasing adoption of personalized medicine, superior efficacy in treating specific molecular subtypes, and fewer side effects compared to traditional chemotherapy. Targeted therapies, such as HER2 inhibitors, have shown substantial success in treating IDC patients, driving their market dominance. For instance, the U.S. FDA authorized Enhertu in April 2024 for the treatment of adult patients with solid tumors that are HER2-positive and metastatic after systemic treatment but do not have adequate alternatives. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing clinical evidence supporting its effectiveness, particularly in cases where traditional treatments have failed. Immunotherapy’s ability to harness the body’s immune system to fight cancer, along with promising results in combination therapies, is expected to significantly boost its demand.
By type, the hormone receptor segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the high prevalence of hormone receptor-positive IDC cases and the effectiveness of hormone therapies like tamoxifen and aromatase inhibitors in managing these types of cancers. Hormone receptor-positive breast cancer treatments remain widely used and generate substantial revenue. For instance, Gilead Sciences stated in February 2023 that the U.S. FDA has approved Trodelvy for a third indication. Through its approval, patients with the most common kind of breast cancer now have an extra therapy choice. Those with metastatic breast cancer, particularly those of the HR-positive/HER2-negative form, who had already undergone at least two systemic treatments and were no longer responding to hormone therapy were the first to be approved for trodelvy. Additionally, the HER2+ segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel HER2-targeting drugs and the increasing use of advanced HER2 inhibitors in patients with aggressive forms of IDC. Innovations in HER2-positive breast cancer treatment, such as the introduction of more potent drugs and combination therapies, are expected to drive rapid growth in this segment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global invasive ductal carcinoma treatment market in 2023 owing to the large volume of cancer treatments administered in hospitals, specialized oncology centers, and the availability of advanced therapies primarily through hospital settings. Patients undergoing complex treatments like chemotherapy and immunotherapy often receive medications directly from hospital pharmacies. For instance, the Max Foundation, working with partners and oncologists, established a program in June 2023 to address the pressing unmet need in low-income nations by giving patients with HR+/HER2- advanced breast cancer access to therapy. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing convenience of online purchasing, growing digital healthcare infrastructure, and the rising demand for home-based care. The shift towards telemedicine and e-commerce, especially following the COVID-19 pandemic, has spurred the growth of online pharmacies, making it easier for patients to access cancer medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to a well-established healthcare infrastructure, high prevalence of breast cancer, and access to advanced treatments. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing healthcare investments, rising cancer awareness, and growing access to advanced treatment options. For instance, in January 2023, the U.S. FDA authorized elacestrant (Orserdu) for the treatment of advanced ER-positive, HER2-negative breast cancer in postmenopausal women and adult males. This medication is especially useful for patients whose cancer has progressed following at least one endocrine therapy line and who have an ESR1 mutation.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Therapy, Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Invasive Ductal Carcinoma Treatment Market Report 2023 - 2034
Invasive Ductal Carcinoma Treatment Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
Invasive Ductal Carcinoma Treatment Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Hormone Receptor
- HER2+
Invasive Ductal Carcinoma Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Invasive Ductal Carcinoma Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Invasive Ductal Carcinoma Treatment Market: Therapy Estimates & Trend Analysis
8. Invasive Ductal Carcinoma Treatment Market: Type Estimates & Trend Analysis
9. Invasive Ductal Carcinoma Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Invasive Ductal Carcinoma Treatment Market
12. Europe Global Invasive Ductal Carcinoma Treatment Market
13. Asia Pacific Global Invasive Ductal Carcinoma Treatment Market
14. Latin America Global Invasive Ductal Carcinoma Treatment Market
15. MEA Global Invasive Ductal Carcinoma Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Roche Holding AG
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Sanofi S.A.
- Gilead Sciences Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Seattle Genetics Inc.
- AbbVie Inc.
- Johnson & Johnson.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 9.37 Billion |
| Forecasted Market Value ( USD | $ 23.02 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
